Cancer Treatment Market Research Reports & Industry Analysis
Cancer is a disease characterized by uncontrolled cell proliferation. Of the more than 100 types of cancer, lung, breast, and colorectal cancer account for nearly half of new cases per year in the United States. Lung cancer, which is highly correlated with cigarette smoking, is responsible for more deaths than any other form of cancer. Cigarette smoking and other environmental factors are associated with the majority of cancers.
With the growing incidence of cancer, a growing and aging world population and significant medical advances, there will continue to be phenomenal growth in the market for cancer diagnosis and treatment products.
Cancer Treatment Industry Research & Market Reports
-
Cervical Cancer Treatment
... at a CAGR of 6.0% over the analysis period 2024-2030. Squamous Cell Carcinoma (SCC), one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$9.1 Billion by the ... Read More
-
Alpha Emitters
... CAGR of 20.9% over the analysis period 2024-2030. Bone Metastasis, one of the segments analyzed in the report, is expected to record a 20.4% CAGR and reach US$993.8 Million by the end of the analysis ... Read More
-
Breast Cancer Screening
... at a CAGR of 5.1% over the analysis period 2024-2030. Imaging Test, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$4.8 Billion by the end of ... Read More
-
Leukemia Therapeutics
... CAGR of 5.6% over the analysis period 2024-2030. Chronic Myeloid Leukemia, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$9.1 Billion by the end of the ... Read More
-
Sunitinib Malate
... CAGR of 9.6% over the analysis period 2024-2030. Pancreatic Neuroendocrine Tumor Application, one of the segments analyzed in the report, is expected to record a 10.9% CAGR and reach US$111.6 Million by the end of ... Read More
-
NDDS in Cancer Therapy
... 2030, growing at a CAGR of 20.7% over the analysis period 2024-2030. Nanoparticles, one of the segments analyzed in the report, is expected to record a 20.6% CAGR and reach US$67.8 Billion by the end ... Read More
-
Liver Cancer Diagnostics
... at a CAGR of 7.4% over the analysis period 2024-2030. Laboratory Tests, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$9.8 Billion by the end of ... Read More
-
Oral Cancer Treatment
... at a CAGR of 3.6% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$1.2 Billion by the end of the ... Read More
-
Metastatic Bone Disease
... at a CAGR of 6.7% over the analysis period 2024-2030. Medication, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$12.3 Billion by the end of the ... Read More
-
Global MHC-Peptide Tetramer Market Insights, Forecast to 2031
... Tetramer is estimated to increase from 63.45 million USD in 2024 to reach 116.42 million USD by 2031, at a CAGR of 9.80% during the forecast period of 2025 through 2031. Europe market for MHC-Peptide ... Read More
-
Cervical Cancer Diagnostic Testing
... 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Pap Smear, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$5.3 Billion by the ... Read More
-
Colposcopy
... 3.9% over the analysis period 2024-2030. Cervical Cancer Screening, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$440.5 Million by the end of the analysis period. ... Read More
-
Non-Small Cell Lung Cancer (NSCLC) Therapeutics
... reach US$54.0 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach ... Read More
-
Oncology Based In-Vivo CRO
... 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Solid Tumors, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$1.2 Billion by the ... Read More
-
Cancer Registry Software
... at a CAGR of 9.6% over the analysis period 2024-2030. Standalone, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$116.6 Million by the end of the ... Read More
-
Cancer Stem Cells
... at a CAGR of 8.5% over the analysis period 2024-2030. Stem Cell-based Cancer Therapy, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$1.3 Billion by the ... Read More
-
Antineoplastic Agents
... CAGR of 7.3% over the analysis period 2024-2030. Chemotherapeutic Agents, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$137.9 Billion by the end of the analysis ... Read More
-
Cancer Biomarkers
... CAGR of 16.9% over the analysis period 2024-2030. Protein Biomarkers, one of the segments analyzed in the report, is expected to record a 17.4% CAGR and reach US$42.9 Billion by the end of the analysis ... Read More
-
Cancer Immunotherapy
... CAGR of 13.7% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 14.5% CAGR and reach US$266.2 Billion by the end of the analysis ... Read More
-
Cervical Cancer Endoscopic Devices
... 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Optical Colposcopes, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$668.1 Million by the ... Read More
-
Cancer Cachexia
... CAGR of 5.7% over the analysis period 2024-2030. Progestogens, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$1.5 Billion by the end of the analysis period. ... Read More
-
Hematological Malignancies
... CAGR of 6.2% over the analysis period 2024-2030. Leukemia, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$33.3 Billion by the end of the analysis period. ... Read More
-
Non-Melanoma Skin Cancer
... at a CAGR of 4.4% over the analysis period 2024-2030. Basal Cell Carcinoma (BCC), one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$835.6 Million by the ... Read More
-
Oncology Information Systems
... at a CAGR of 6.2% over the analysis period 2024-2030. Software, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$5.5 Billion by the end of the ... Read More
-
Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious, Neurological), Application (Diagnostic, Research) - Global Forecast to 2030
... to the advantage that these assay kits offer standardized and optimized protocols, facilitating accurate and efficient analysis of biomarkers in various biological samples, thus contributing significantly to diagnostic and research endeavors in healthcare. Further, advances ... Read More
Research Assistance
